Abstract
Objective: Coronavirus Disease-2019 (COVID-19) is a pandemic outbreak in the world and is the leading cause of Severe Acute Respiratory Syndrome (SARS).
Methods: Currently, many drugs/therapies have been tested for COVID-19, which responded sub- -optimally to the patients. Remdesivir is an RNA polymerase inhibitor that found promising results in ongoing clinical trials and shows a faster recovery rate in COVID-19 patients. Currently, USFDA approves for emergent use of this drug in severe COVID-19 patients. Results: In this review, we discussed a brief overview of biopharmaceutical and pharmacological aspects of Remdesivir. Moreover, the ongoing regulatory status of Remdesivir by official bodies has also been described.Keywords: Remdesivir, COVID-19, USFDA, SARS, WHO, RNA polymerase inhibitor.
Graphical Abstract
Related Journals
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Anti-Infective Agents
Recent Advances in Inflammation & Allergy Drug Discovery
Current Medicinal Chemistry
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Endocrine, Metabolic & Immune Disorders - Drug Targets
Related Books
Antibodies Applications and New Developments
Frontiers in Inflammation
Frontiers in Inflammation
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research – Anti Allergy Agents
Immunology of Pregnancy 2013
Meta-Inflammation and Obesity
19